Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Pilot Study Evaluating Immune Impact and Safety of Nivolumab in Combination with Ipilimumab (immune Combination) Before Initial RT-CT Treatment for Cervix Cancer.: the French GINECO - COLIBRI Study

Next Previous
Search
Trial Profile

A Multicenter, Pilot Study Evaluating Immune Impact and Safety of Nivolumab in Combination with Ipilimumab (immune Combination) Before Initial RT-CT Treatment for Cervix Cancer.: the French GINECO - COLIBRI Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Cervical cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Acronyms COLIBRI; GINECO-COLIBRI

    • Most Recent Events

    • 12 Dec 2024 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Primary endpoint (CD8+/FOXP3+ relative change of lymphocytes from pre to post treatment biopsies) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results assessing the in-situ impact of combination of nivolumab plus ipilimumab in patients with cervical squamous carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top